Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)

This study has been terminated.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: December 23, 2004
Last updated: May 25, 2015
Last verified: May 2015
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: October 2006
  Primary Completion Date: September 2006 (Final data collection date for primary outcome measure)